(Q37587178)

21 August 2017

1 reference

title

Emerging drugs for insomnia: new frontiers for old and novel targets (English)

1 reference

21 August 2017

0 references

Christian Guilleminault

series ordinal

2

object named as

Christian Guilleminault

0 references

author name string

Shannon S Sullivan

series ordinal

1

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Expert Opinion on Emerging Drugs

21 August 2017

published in

1 reference

21 August 2017

volume

14

1 reference

21 August 2017

issue

3

1 reference

21 August 2017

page(s)

411-422

1 reference

Epidemiology of insomnia: what we know and what we still need to learn

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

CAP variables and arousals as sleep electroencephalogram markers for primary insomnia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Cognitive Effects of Long-Term Benzodiazepine Use

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Ramelteon for the treatment of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Residual effects of hypnotics: epidemiology and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Long-term use of sedative hypnotics in older patients with insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Hypothalamic regulation of sleep and circadian rhythms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Effect of zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: a 4-week, randomized, multicenter, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

5-HT(2A) inverse-agonists for the treatment of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Efficacy and tolerability of indiplon in older adults with primary insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Indiplon: a nonbenzodiazepine sedative-hypnotic for the treatment of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Lack of generalisation between the GABAA receptor agonist, gaboxadol, and allosteric modulators of the benzodiazepine binding site in the rat drug discrimination procedure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

The selective extrasynaptic GABAA agonist, gaboxadol, improves traditional hypnotic efficacy measures and enhances slow wave activity in a model of transient insomnia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Efficacy of the selective extrasynaptic GABA A agonist, gaboxadol, in a model of transient insomnia: a randomized, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Melatonin and melatonergic drugs on sleep: possible mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Laboratory and field studies of naps and caffeine as practical countermeasures for sleep-wake problems associated with night work

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Promotion of sleep by targeting the orexin system in rats, dogs and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Orexin receptor antagonists: medicinal chemistry and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Casopitant: a new warrior in the antiemetic crusade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903171948

10.1517/14728210903171948

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference